mTHPC pharmacokinetics following topical administration

Ann Johansson; Jenny Svensson; Stefan Andersson-Engels; Niels Bendsoe; Katarina Svanberg M.D.; Irving Bigio; Eleni Alexandratou; Maria Kyriazi; Dido Yova; Susanna Gräfe; Tilmann Trebst

doi:10.1117/12.647602

27 February 2006 mTHPC pharmacokinetics following topical administration

Ann Johansson, Jenny Svensson, Stefan Andersson-Engels, Niels Bendsoe, Katarina Svanberg M.D., Irving Bigio, Eleni Alexandratou, Maria Kyriazi, Dido Yova, Susanna Gräfe, Tilmann Trebst

Author Affiliations +

Proceedings Volume 6094, Optical Diagnostics and Sensing VI; 60940C (2006) https://doi.org/10.1117/12.647602
Event: SPIE BiOS, 2006, San Jose, California, United States

Abstract

Measurements of concentration of sensitizers for photodynamic therapy can provide important information in the dosimetry planning and can also give input to the optimal time for treatment. There has been skepticism towards fluorescence techniques for this purpose, as the signal depends on the fluorescence yield and optical properties of the tissue. Absorption based techniques, lack on the other hand, often the sensitivity required for many sensitizers with relative weak absorption in a wavelength region where hemoglobin absorption is dominant. A direct comparison between absorption and fluorescence techniques for measuring mTHPC concentration after topical application on hairless SKH-1 mice bearing skin carcinomas has been performed. 20 μl/cm² of m-THPC thermogel (0.5 mg m-THPC/ml) were applied on normal and tumor area and the concentration of mTHPC was measured at 4 and 6 hours after drug application by two methods: 1. A fluorescence imaging system capturing images at two wavelengths (500 and 650 nm) following 405 nm excitation. Signals from different regions of interest were averaged and the intensity ratio at 650 to 500 was calculated. 2. A diffuse reflectance spectroscopy system with a fiber separation of 2 mm, providing the absorbance at 652 nm. Both systems provided consistent results related to the photosensitizer concentration. The methods show a remarkable difference in the concentration of photosensitizer in normal skin and tumor. No significant difference in mTHPC concentration in tumor could be observed between the 4 and 6h groups after drug application.

Citation Download Citation

Ann Johansson, Jenny Svensson, Stefan Andersson-Engels, Niels Bendsoe, Katarina Svanberg M.D., Irving Bigio, Eleni Alexandratou, Maria Kyriazi, Dido Yova, Susanna Gräfe, and Tilmann Trebst "mTHPC pharmacokinetics following topical administration", Proc. SPIE 6094, Optical Diagnostics and Sensing VI, 60940C (27 February 2006); https://doi.org/10.1117/12.647602

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available